Alterity Therapeutics Limited (ATH:ASX)

3.8¢

right-arrow Created with Sketch. -0.001 (-2.56%)
Last trade 15.48pm 23/10/2020 20mins delayed

Latest Announcements

11.48am 23/10/2020 Price SensitivePSATHAlterity Therapeutics Limited
11.44am 23/10/2020ATHAlterity Therapeutics Limited
20/10/2020ATHAlterity Therapeutics Limited
16/10/2020ATHAlterity Therapeutics Limited
16/10/2020ATHAlterity Therapeutics Limited
16/10/2020 Price SensitivePSATHAlterity Therapeutics Limited
12/10/2020 Price SensitivePSATHAlterity Therapeutics Limited
4,315
MCap
06/10/2020ATHAlterity Therapeutics Limited
357
MCap

Company Overview

Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

ATH in the news

Search Previous Announcements